Merck Reports the CHMP’s Positive Opinion of Keytruda Plus CT as a 1L Treatment of Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
Shots:
- The CHMP has granted positive opinion to Keytruda + pemetrexed & Pt-based CT as a 1L treatment of adults with unresectable non-epithelioid MPM, with the EC’s decision anticipated in Q4’24. The regimen was approved across the US in Sep 2024 for the same
- The opinion was based on the P-II/III (IND.227/KEYNOTE-483) study assessing Keytruda + CT vs CT alone, showing improved OS
- Study depicted a reduction in the death risk by 21%, with mOS of 17.3 vs 16.1mos., significantly improved PFS, with mPFS of 7.1mos. in both the arms and ORR of 52% vs 29%
Ref: Merck | Image: Merck
Related News:- Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
